Could a common drug slow Alzheimer's? new trial aims to find out
NCT ID NCT04629495
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 23 times
Summary
This study tests whether the drug rapamycin is safe and tolerable for older adults with mild cognitive impairment or early Alzheimer's disease. Over 12 months, 40 participants will take oral rapamycin to see how it affects their health and thinking. The goal is to gather initial safety data, not to cure the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases
RECRUITINGSan Antonio, Texas, 78229, United States
Contact Phone: •••-•••-••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.